The “Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering.
This pipeline guide provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape.
The guide provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.
The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered
Introduction
Report Coverage
Overview
Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Companies Involved in Therapeutics Development
- Asarina Pharma AB
- Emalex Biosciences Inc
- Evero Health Ltd
- Noema Pharma AG
- Octapharma AG
- SOM Biotech SL
Drug Profiles
- Bevantolol
- Dronabinol + Palmidrol
- Ecopipam hydrochloride
- Immune globulin (human)
- NOE-105
- Sepranolone
- Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders
Dormant Projects
Discontinued Products
Product Development Milestones
Featured News & Press Releases
- Feb 16, 2022: First patient in for landmark Tourette Syndrome study
- Jan 18, 2022: SciSparc advances its phase IIb clinical trial in patients with Tourette syndrome with its proprietary drug candidate SCI-110
- Dec 22, 2021: Asarina Pharma receives final approval for landmark phase IIa Tourette study
- Dec 08, 2021: Noema Pharma hosting key opinion leader webinar on Stuttering
- Nov 10, 2021: Paragon’s portfolio company Emalex Biosciences announces positive topline results from phase 2bclinical study evaluating ecopipam for pediatric Tourette syndrome
- Sep 16, 2021: Administrative backlog at public authority causes short-term delay in Tourette study
- Aug 05, 2021: Noema Pharma initiates phase 2a Allevia study of PDE10A inhibitor NOE-105 in Tourette Syndrome
- Jul 26, 2021: SciSparc announces updates regarding its phase IIb study in Tourette Syndrome
- Jun 22, 2021: Emalex Biosciences announces completion of patient enrollment in phase 2b clinical trial evaluating Ecopipam (EBS-101) for pediatric patients with Tourette Syndrome
- Jun 08, 2021: Asarina Pharma granted US patent for Sepranolone for Tourette syndrome, OCD and pathological gambling
- May 19, 2021: Asarina Pharma receives approval of CTA for phase IIa Tourette study
- Feb 11, 2021: New preclinical study confirms that Sepranolone suppresses tics in Tourette Syndrome
- Feb 10, 2021: SciSparc engages Procaps for development and production of CannAmide and its SCI-110 product candidate
- Sep 01, 2020: Emalex Biosciences Phase 2b Tourette Syndrome clinical trial reaches enrollment milestone
- Mar 24, 2020: Asarina Pharma to release historic Phase IIb PMDD data on schedule
For more information about this report visit https://www.researchandmarkets.com/r/9p6tco
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets